Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

NCT05286788 is registered in ClinicalTrials.gov with Nationwide Children's Hospital as lead sponsor.

NCT NCT05286788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05286788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Lead sponsor
Nationwide Children's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 10, 2023
Completion date
April 10, 2027
Enrollment
38 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

adamantinous craniopharyngioma, recurrent adamantinomatous craniopharyngioma